You are here: Home » News-IANS » Health-Medicine
Business Standard

Vitamin E supplements may speed up lung cancer: Study

IANS  |  London 

In an alarming study, scientists have found that two commonly used antioxidants - including the popular vitamin E - can fuel the growth of lung cancer in mice rather than curb it.

"The take-home message is that these antioxidants do not decrease the risk of cancer and may even increase risk of some cancers in some populations," cautioned Martin Bergö, a molecular biologist at University of Gothenburg in Sweden and a co-author of the latest study.

Bergö and his colleague, Per Lindahl, a molecular biologist at the University of Gothenburg, conducted experiments in mice that were genetically engineered to develop lung cancer.

They first decided to dose the mice with a compound called N-acetylcysteine (NAC) - another antioxidant.

The control tumours grew three times faster than expected after the NAC dose.

The team decided to dig deeper, and expanded its study to include another common antioxidant - vitamin E, said a report in Nature.

The researchers fed either NAC or vitamin E to the mice, using doses of 5 or 50 times higher than the daily recommended amount for mice.

Human dietary supplements often have 4 to 20 times the recommended daily intake of vitamin E (22.4 EU) for humans.

The results for the two antioxidants were similar. Tumours grew about three times faster than those in animals that did not receive the treatment.

Treated mice also died from their cancers about twice as quickly as untreated mice, said the study published in the journal Science Translational Medicine.

"Our study, however, does not say anything about how antioxidant supplementation affects cancer risk in apparently healthy people," the study added.

According to Lindahl, the work does call for a closer look at the effects of antioxidants in smokers, who are at high risk for lung cancer and may already carry small tumours while outwardly seeming healthy.

He is also concerned about people with a common lung ailment called chronic obstructive pulmonary disease, who are sometimes treated with NAC to reduce mucus production.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, January 30 2014. 18:30 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU